Trial Profile

A Phase 3 study of Sonelokimab in psoriatic-arthritis

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonelokimab (Primary)
Indications Psoriatic arthritis
Focus Registrational; Therapeutic Use
Sponsors MoonLake Immunotherapeutics

Most Recent Events

10 Jun 2024 According to a MoonLake Immunotherapeutics media release, the company announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have provided positive feedback on this clinical trial
29 Feb 2024 New trial record
26 Feb 2024 According to a MoonLake Immunotherapeutics media release, company plans to have an end-of-Phase 2 meeting with the FDA regarding its psoriatic arthritis (PsA) program in Q2 2024 and begin the Phase 3 program in Q4 2024. Company will provide more information relating to the plans for the PsA programs during an upcoming R&D Day.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com